Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company's core products are experiencing stable growth, with a high dividend payout ratio maintained above 80% for two consecutive years [4][6]. - In 2024, the company achieved a revenue of 2.578 billion yuan, a year-on-year increase of 32.71%, and a net profit attributable to shareholders of 508 million yuan, also up by 32.60% [4]. - For Q1 2025, the company reported a revenue of 824 million yuan, reflecting a year-on-year growth of 22.52%, and a net profit of 181 million yuan, up by 27.20% [4]. Summary by Sections Revenue and Profit Growth - The company’s core product, Wuling Mushroom Powder, is a new type of traditional Chinese medicine, contributing significantly to revenue. In 2024, the Wuling series generated 1.438 billion yuan, a growth of 17.14%, accounting for 55.79% of total revenue [6]. - The company expects revenue for 2025, 2026, and 2027 to be 3.263 billion, 4.115 billion, and 5.120 billion yuan respectively, with growth rates of 27%, 26%, and 24% [8]. Cost Management and Efficiency - The company has shown significant cost reduction and efficiency improvements, with a sales expense ratio of 32.53%, down by 7.5 percentage points year-on-year, and a management expense ratio of 4.28%, down by 0.7 percentage points [6]. Dividend Policy - The company plans to distribute a cash dividend of 415 million yuan for 2024, maintaining a dividend payout ratio exceeding 80% [6]. Earnings Forecast - The forecasted net profit for 2025, 2026, and 2027 is 662 million, 861 million, and 1.101 billion yuan respectively, with corresponding growth rates of 30% for 2025 and 2026, and 28% for 2027 [8].

创业板公司最新融资余额3355.23亿元，已连续三个交易日减少，其间累计减少20.99亿元。 融资余额增幅超10%的个股中，以所属行业统计，主要集中在医药生物、电力设备、基础化工行业，分 别有8只、7只、6只个股上榜。 市场表现方面，融资余额增幅超10%的个股中，其间平均上涨1.82%，表现强于创业板指，涨幅居前的 有联合化学、华康洁净、肇民科技，分别上涨38.41%、12.69%、12.08%，跌幅居前的有芒果超媒、宏 工科技、美好医疗，分别下跌14.76%、13.49%、11.17%。 创业板融资余额连降期间，以金额统计，融资余额增加最多的是新易盛，最新融资余额为33.42亿元， 其间增加1.72亿元，融资余额增加较多的还有佐力药业、指南针、芒果超媒等，分别增加1.58亿元、 1.07亿元、9200.18万元。融资余额减少较多的有东方财富、润泽科技、胜宏科技等，分别减少5.16亿 元、2.13亿元、1.81亿元。（数据宝） 证券时报·数据宝统计显示，截至4月28日，创业板两融余额合计3363.90亿元，较上一交易日减少4.68亿 元。其中，融资余额合计3355.23亿元，较上一交易日减少4.53亿元，为连 ...

盘面上，PEEK材料概念涨超2%，肯特股份（301591）、新瀚新材（301076）等涨超10%，中研股份、 富恒新材等涨超5%。 4月28日早盘，A股市场主要指数震荡走弱，钢铁、银行、电力、互联网电商等逆市涨幅居前。 超超临界发电概念涨幅居前，华电能源（600726）、华银电力（600744）、京能电力（600578）等涨 停。 10股杠杆资金加仓超1亿元 截至4月25日，市场融资余额合计1.79万亿元，较前一交易日减少54.02亿元。 具体到个股，4月25日获融资净买入千万元以上的有250只，其中10只融资净买入额超1亿元。招商蛇口 （001979）融资净买入额居首，当日净买入2.01亿元；其次是比亚迪（002594）、拓维信息 （002261），融资净买入金额分别为1.94亿元、1.72亿元；融资净买入金额居前的还有寒武纪、浙江荣 泰（603119）、佐力药业（300181）等。 | 4月25日融资净买入居前个股 | | | | | | | --- | --- | --- | --- | --- | --- | | 融资净买入 代码 | | (亿元) | 最新融资余 额(亿元) | 占流通市值 比例 ( ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's profitability is steadily improving, with revenue and profit reaching a new quarterly high [1] - The core products are showing robust growth, and the company's profit margins are being maintained despite price pressures from collective procurement [8] - The company is expected to continue its growth trajectory, particularly in the OTC market, while maintaining a high dividend payout ratio [8] Financial Performance Summary - Total revenue for 2024 is projected at 25.78 billion yuan, a year-on-year increase of 32.71% [8] - Net profit attributable to shareholders for 2024 is expected to be 5.08 billion yuan, also reflecting a 32.60% increase [8] - The earnings per share (EPS) for 2024 is forecasted to be 0.72 yuan, with a price-to-earnings (P/E) ratio of 21.99 [1][9] Product Performance Summary - The revenue from the Wuling series is expected to reach 14.38 billion yuan in 2024, with a year-on-year growth of 17.14% [8] - The Chinese herbal medicine series is projected to generate 6.73 billion yuan in revenue, marking a significant increase of 46.02% [8] - The revenue from Chinese herbal formula granules is anticipated to grow by 143.19%, reaching 1.02 billion yuan [8] Future Projections - The company’s net profit is projected to reach 6.55 billion yuan in 2025 and 8.41 billion yuan in 2026, with corresponding P/E ratios of 17 and 13 [8] - By 2027, the net profit is expected to reach 10.41 billion yuan, with a P/E ratio of 11 [1][9]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The Chinese traditional medicine sector is expected to experience a relative recovery in 2025, with opportunities in key lines and individual stocks [4][12] - The overall market demand is gradually recovering due to the end of the pandemic and the impact of influenza, leading to a high base and inventory digestion pressure in 2024 [4][12] - The State Council's March 2025 document supports the quality improvement of traditional Chinese medicine, which is expected to stimulate innovation and commercialization of high-quality products [5][13] Summary by Sections Industry Trends - In April 2025, the pharmaceutical and biotechnology sector rose by 1.16%, outperforming the CSI 300 index by 0.77 percentage points [6][15] - The medical research outsourcing sector saw the largest increase of 6.34%, while the vaccine sector experienced the largest decline of 3.78% [20][21] Investment Opportunities - Four main investment lines are identified: 1. Innovative R&D-focused companies with strong capabilities, benefiting from accelerated approvals and optimized procurement, recommended stocks include Fangsheng Pharmaceutical, Yuyuan Pharmaceutical, Tianshili, and Yiling Pharmaceutical [5][14] 2. State-owned enterprises undergoing operational efficiency improvements, recommended stocks include Dong'e Ejiao, Jiangzhong Pharmaceutical, and Kunming Pharmaceutical [5][14] 3. Companies with strong brand power and relatively scarce products, recommended stocks include Zoli Pharmaceutical and Lingrui Pharmaceutical [5][14] 4. Companies experiencing turnaround and valuation recovery, recommended stock includes Jichuan Pharmaceutical [5][14] Market Performance - The traditional Chinese medicine sector has faced pressure since the pandemic, but the situation is expected to improve in 2025 as macro disturbances ease [4][12] - The price index of traditional Chinese medicine materials has been declining since mid-July 2024, which is expected to alleviate the gross margin pressure on companies in 2025 [5][12]

Group 1: Company Performance Overview - The company's OTC sales revenue accounts for approximately 10% of total sales, with a strategy focused on expanding the OTC market and enhancing product accessibility and repurchase rates [2] - In Q1 2025, online sales showed significant growth, although the overall online sales proportion remains low [3] - The company aims to develop the Wuling Capsule into a large-scale product with a target of 2 billion in sales, leveraging its presence in 15,000 medical institutions [4] Group 2: Sales Growth and Product Performance - The sales volume of Lingze Tablets increased by 23.17% in 2024, with Q1 2025 sales volume and revenue growing by 22.49% and 23.39% respectively [4] - The Chinese herbal medicine segment saw a 26.39% growth in Q1 2025, with the company operating over 1,000 product specifications and 180 cooperative herbal planting bases [5] - The Chinese herbal formula granules achieved a revenue of 102 million in 2024, with a 50.64% increase in Q1 2025 compared to the previous year [5] Group 3: Financial Management and Challenges - The net cash flow from operating activities significantly decreased in Q1 2025 due to increased period expenses and prepayments for raw materials [8] - Accounts receivable increased due to higher sales revenue and the growth in income from herbal formula granules and commercial circulation [9] - The company is implementing dynamic management of sales expenses, aligning spending with development stages and sales cycles [7]

Core Viewpoint - The company has reported its annual results, highlighting its main business in pharmaceutical research, production, and sales, with a focus on traditional Chinese medicine and innovative drug development [1][2]. Company Overview - The company specializes in the research, production, and sales of pharmaceuticals, with key products including various traditional Chinese medicine formulations and innovative drugs targeting specific health conditions [2][3]. Main Products - **Wuling Capsule**: A unique product and a national class I new drug, primarily used in various medical fields for its cognitive enhancement and anxiety relief properties. It has been included in 80 clinical guidelines and expert consensus documents [2][3]. - **Lingze Tablet**: An innovative drug for benign prostatic hyperplasia, recognized for its unique mechanism of action and included in 12 clinical guidelines [3]. - **Linglianhua Granules**: A product aimed at alleviating menopausal symptoms, now classified as a non-prescription drug and recommended in clinical guidelines [4]. - **Bailing Tablet and Capsule**: Both products are used for respiratory and renal conditions, with significant clinical research supporting their efficacy in chronic obstructive pulmonary disease and chronic kidney disease [4][5]. - **Psyllium Calcium Tablet**: A first generic drug for irritable bowel syndrome, recommended in multiple clinical guidelines for its safety and efficacy in treating constipation [5]. Financial Data and Shareholder Information - The company has undergone a change in its accounting firm, now audited by Zhonghui Accounting Firm, and has proposed a cash dividend of 6.00 yuan per 10 shares [1]. - As of the report date, the company has a total of 14,895,074 shares held in its repurchase account, representing 2.12% of the total share capital [8]. Important Events - The company received a drug registration certificate for Bailing Capsule from the National Medical Products Administration [9]. - The company has adjusted the timeline for several fundraising investment projects, including the construction of an intelligent traditional Chinese medicine production base [10]. - A strategic cooperation framework agreement was signed with Lingyi (Hangzhou) Biotechnology Co., Ltd. to enhance collaboration in the pharmaceutical sector [14].

Core Viewpoint - Zhaoli Pharmaceutical announced a cash dividend plan for the year 2024, proposing a distribution of 6 yuan per 10 shares (including tax), totaling approximately 415 million yuan, which represents 81.82% of the net profit and a dividend yield of 4.23% based on the average trading price for the year [2][3]. Company Summary - Zhaoli Pharmaceutical's revenue for 2024 reached 2.578 billion yuan, marking a year-on-year increase of 32.71%, while net profit was 508 million yuan, also up by 32.60%. The basic earnings per share stood at 0.73 yuan, with a weighted average return on equity of 18.55% [2]. - The company has distributed dividends 14 times since its listing, with the latest proposal being the highest payout per share to date [2][3]. Industry Summary - In the pharmaceutical and biotechnology sector, 223 companies have announced their dividend plans for 2024. WuXi AppTec leads with a total cash distribution of 7.692 billion yuan, followed by Yunnan Baiyao and Heng Rui Medicine with distributions of 2.114 billion yuan and 1.275 billion yuan, respectively [3]. - Zhaoli Pharmaceutical ranks among the top companies in terms of cash distribution, with a payout of 415 million yuan, which is 81.82% of its net profit, placing it favorably within the industry [4].

证券代码：300181 证券简称：佐力药业 公告编号：2025-026 浙江佐力药业股份有限公司 本次网上业绩说明会将采用网络互动方式举行，投资者可于 2025 年 4 月 30 日前访问网址 http://roadshow.eastmoney.com/luyan/4699854 进行会前提 问，公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注的 问题进行回答。 出席本次 2024 年度网上业绩说明会的人员有：董事长俞有强先生，董事、 总经理汪涛先生，董事、常务副总经理冯国富先生，独立董事朱建先生，副总经 理兼财务总监叶利女士，董事会秘书吴英女士。 欢迎广大投资者积极参与本次网上业绩说明会！ 关于举行 2024 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江佐力药业股份有限公司（以下简称"公司"）（以下简称"公司"）已 于 2025 年 4 月 25 日在巨潮资讯网（http://www.cninfo.com.cn）披露了《2024 年年度报告》及《2024 年年度报告摘要》。 为便于广大投资者更深入全面地了解公司 ...

公司着眼于长远和可持续发展，在综合考虑公司发展战略规划、公司实际情 况和发展目标、股东要求和意愿、社会资金成本以及外部融资环境等因素的基础 上，结合公司当前及未来盈利规模、现金流量状况、发展所处阶段、项目投资资 金需求、外部融资环境等情况，建立对投资者持续、稳定、科学的回报规划与机 制，从而对利润分配做出制度性安排，以保证利润分配政策的连续性和稳定性。 二、公司制定《股东回报规划》的制定原则 在符合国家相关法律、法规及《公司章程》的前提下，公司将充分重视对投 资者的合理投资回报并兼顾公司的可持续发展，在充分考虑股东利益的基础上确 定合理的利润分配方案，保持公司利润分配政策的连续性和稳定性。公司在利润 分配政策的研究论证和决策过程中，应充分考虑独立董事和公众股东的意见。 三、未来三年（2025 年-2027 年）具体股东回报规划 （一）利润分配原则：公司实行持续、稳定的利润分配政策，公司利润分配 应重视对投资者的合理投资回报，并兼顾公司的可持续发展。利润分配不得超过 累计可分配利润的范围，不得损害公司持续经营能力。公司董事会、监事会和股 东大会对利润分配政策的决策和论证过程中应当充分考虑独立董事、外部监事和 公 ...